Cargando…

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study

INTRODUCTION: Mutations in KIT proto-oncogene, receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor-α (PDGFRA) render the available tyrosine kinase inhibitors (TKI) ineffective in treating advanced gastrointestinal stromal tumors (GIST). Ripretinib, a broad-spectrum switch-cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Weili, Qian, Haoran, Yang, Litao, Wang, Pengfei, Qian, Hailong, Chu, Binbin, Liu, Zhuo, Sun, Jingyu, Wu, Dan, Sun, Lifeng, Zhou, Wenqiang, Hu, Jingwei, Chen, Xiaolei, Shou, Chunhui, Ruan, Lingxiang, Zhang, Yunyun, Yu, Jiren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233743/ https://www.ncbi.nlm.nih.gov/pubmed/37274264 http://dx.doi.org/10.3389/fonc.2023.1180795

Ejemplares similares

Ripretinib for gastrointestinal stromal tumours
Publicado: (2021)

Ripretinib for the treatment of advanced gastrointestinal stromal tumor
por: Zalcberg, John R.
Publicado: (2021)

Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward
por: Lostes-Bardaji, M. Julia, et al.
Publicado: (2021)

Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors
por: Thirasastr, Prapassorn, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
por: Liao, Weiting, et al.
Publicado: (2021)

Multiple gastrointestinal stromal tumors: analysis of clinicopathologic characteristics and prognosis of 20 patients
por: Li, Kai, et al.
Publicado: (2019)

Correction to: Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Management of Patients With Advanced Gastrointestinal Stromal Tumor: Emphasis on Fourth-Line Treatment With Ripretinib
por: Brackert, Sandra, et al.
Publicado: (2023)

Relationship of prognostic nutritional index with prognosis of gastrointestinal stromal tumors
por: Sun, Jianyi, et al.
Publicado: (2019)

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

The prognostic role of gastrointestinal bleeding in patients with a primary gastrointestinal stromal tumor: a long-term follow-up study
por: Shi, Xiaoxiao, et al.
Publicado: (2023)

Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
por: Zhang, Xinhua, et al.
Publicado: (2023)

Advances in the diagnosis of non-occlusive mesenteric ischemia and challenges in intra-abdominal sepsis patients: a narrative review
por: Chen, Zhou, et al.
Publicado: (2023)

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
por: Janku, Filip, et al.
Publicado: (2020)

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
por: Zalcberg, John R., et al.
Publicado: (2021)

Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
por: Janku, F., et al.
Publicado: (2022)

Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report
por: Huang, Shaoqing, et al.
Publicado: (2022)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib
por: Saheb Kashaf, Sara, et al.
Publicado: (2023)

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery
por: Gouda, Mohamed A., et al.
Publicado: (2023)

ypT0 gastric carcinoma after preoperative chemotherapy: a unique status according to AJCC 8(th) edition cancer staging system
por: Zhu, Kankai, et al.
Publicado: (2020)

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
por: Schöffski, Patrick, et al.
Publicado: (2022)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
por: Bauer, Sebastian, et al.
Publicado: (2022)

Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review
por: Zhang, Yefan, et al.
Publicado: (2023)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique
por: Wang, Hui-jun, et al.
Publicado: (2021)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique [Corrigendum]
Publicado: (2023)

Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
por: Li, Jian, et al.
Publicado: (2022)

A rapid and sensitive UPLC-MS/MS method for simultaneous determination of four potential mutagenic impurities at trace levels in ripretinib drug substance
por: Huang, Yiwen, et al.
Publicado: (2022)

The effect of oceanic mesoscale eddies on the looping path of the Kuroshio intrusion in the Luzon Strait
por: Yang, Qian, et al.
Publicado: (2020)

Excited-state electronic properties, structural studies, noncovalent interactions, and inhibition of the novel severe acute respiratory syndrome coronavirus 2 proteins in Ripretinib by first-principle simulations
por: Alharthi, Fahad A., et al.
Publicado: (2021)

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor
por: Li, Xiaoyan, et al.
Publicado: (2022)

Metanephric stromal tumor in an adult with PDGFRA mutation: a case report
por: Guo, Sanjun, et al.
Publicado: (2023)

The Correlation Between Computed Tomography Volumetry and Prognosis of Advanced Gastric Cancer Treated with Neoadjuvant Chemotherapy
por: Chen, Chao, et al.
Publicado: (2020)

The prognostic value of neutrophil–lymphocyte ratio is superior to derived neutrophil–lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential R0 resection: a 5-year follow-up
por: Jin, Hailong, et al.
Publicado: (2017)

In vitro expansion affects the response of human bone marrow stromal cells to irradiation
por: Xiang, Yang, et al.
Publicado: (2019)

Risk Factors and Prognostic Analysis of Gastrointestinal Stromal Tumor Recurrence-Metastasis
por: Chen, Shan, et al.
Publicado: (2022)

Imaging findings of prostate tuberculosis by transrectal contrast-enhanced ultrasound and comparison with 2D ultrasound and pathology
por: Yang, Gaoyi, et al.
Publicado: (2022)

Mesenchymal stromal/stem cells and their extracellular vesicles in liver diseases: insights on their immunomodulatory roles and clinical applications
por: Huai, Qian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2thc7ekv77lde2l66a3ol50ri0